Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Filings indexed 481 across all filing types
Latest filing 2021-02-12 Major Shareholding Noti…
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 3 TO THE SCHEDULE 13G
Major Shareholding Notification
2021-02-12 English
SC 13G/A
Major Shareholding Notification
2021-02-10 English
PRIMARY DOCUMENT
Director's Dealing
2021-02-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions an FDA clinical hold on a Phase 2a clinical trial and includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is short (2964 characters) and primarily serves as a regulatory announcement of an event rather than a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-05 English
PRIMARY DOCUMENT
Director's Dealing
2021-02-04 English
FORM 4 SUBMISSION
Director's Dealing
2021-02-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.